Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

GlobeNewswire February 23, 2022

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

GlobeNewswire January 19, 2022

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

GlobeNewswire January 12, 2022

KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference

GlobeNewswire January 11, 2022

KemPharm to Participate in BIO Partnering @ JPM During "J.P. Morgan Week 2022"

GlobeNewswire January 6, 2022

KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program

GlobeNewswire December 20, 2021

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of "Higher-Dose SDX"

GlobeNewswire December 14, 2021

KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021

GlobeNewswire December 13, 2021

KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida

GlobeNewswire December 13, 2021

KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

GlobeNewswire November 10, 2021

KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

GlobeNewswire November 5, 2021

KemPharm to Report Third Quarter 2021 Results

GlobeNewswire November 3, 2021

AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

GlobeNewswire October 27, 2021

KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)

GlobeNewswire October 20, 2021

KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market

GlobeNewswire October 19, 2021

KemPharm to Present at the Benzinga Healthcare Small Cap Conference

GlobeNewswire September 27, 2021

KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

GlobeNewswire September 23, 2021

KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

KemPharm Appoints Tamara A. Seymour to Board of Directors

GlobeNewswire August 18, 2021

KemPharm Reports Second Quarter 2021 Financial Results

GlobeNewswire August 12, 2021